Kyle Gilde, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 989-772-6732 Fax: 989-772-6810 |
Kenneth Dauphinee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 989-772-6700 Fax: 989-772-6807 |
Mohan V Achwal, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 989-772-6700 Fax: 989-772-6807 |
Michael Gross, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 989-772-6700 Fax: 989-772-6807 |
Dr. Jason Michael Vanhouten, DO Anesthesiology Medicare: Medicare Enrolled Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 740-485-5352 |
Dr. Joon Chong, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1221 South Dr, Mt Pleasant, MI 48858 Phone: 989-772-6700 Fax: 989-772-6807 |
News Archive
VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.
To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.
New animal research helps explain why some eat without hunger or to excess. The studies explore the biological effects of poor eating habits, showing that high-fat diets cause lasting brain changes that may impair healthy eating. Additional studies show that food and drugs of abuse engage many of the same brain systems. The findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.
20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.
A team of Wayne State University researchers was awarded $330,000 from the National Science Foundation (NSF) to develop a 3-D neural probe. Their aim is to develop an implantable device that will suppress tinnitus, a neurological disorder that affects more than 250 million people worldwide.
› Verified 4 days ago